Degenerative aortic valve disease (DAVD) is the most common heart valve pathology and is especially prevalent in the elderly population. Studies have shown that stenosis, the most severe form of DAVD, increases in prevalence from 0.7% in people between 18 and 44 years of age to over 13% of people over 75 years of age. Furthermore, early symptoms of DAVD have been detected in 29% of patients over 65 years of age. These symptoms are associated with a 50% increase in cardiovascular related morbidity and a similar increase in the risk of myocardial infarction [1]. Currently, aortic valve (AV) replacement surgery is the only method available to correct DAVD, and while these procedures have become less invasive, replacement valves are still rather expensive and do not function as well as native valves. Therefore, the development of a therapeutic that could prevent DAVD would greatly benefit many patients.

This content is only available via PDF.
You do not currently have access to this content.